A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy

BACKGROUND: Nivolumab is approved for mRCC patients who have received prior anti-angiogenic therapy but the duration of therapy required for sustained clinical benefit is unknown. A phase II clinical trial to investigate the feasibility of intermittent nivolumab dosing was conducted. METHODS: Patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Ornstein, Moshe C., Wood, Laura S., Hobbs, Brian P., Allman, Kimberly D., Martin, Allison, Bevan, Michael, Gilligan, Timothy D., Garcia, Jorge A., Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524207/
https://ncbi.nlm.nih.gov/pubmed/31097024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0615-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados